| Literature DB >> 3280842 |
F E Young1, J A Norris, J A Levitt, S L Nightingale.
Abstract
The Food and Drug Administration has established new procedures to make promising investigational drugs available for treatment of patients with immediately life-threatening or serious diseases as early in the drug development process as possible and well before general marketing begins. The purpose of this article is to inform the medical community about these new procedures and to facilitate their implementation. Examples of immediately life-threatening and serious diseases are given and the procedures that physicians should use to obtain a drug under the new regulations are described. The treatment use of zidovudine (Retrovir), while still in the investigational phase, is described as a case study. The article also summarizes the Food and Drug Administration's new procedures under which drug sponsors can charge for investigational drugs.Entities:
Mesh:
Substances:
Year: 1988 PMID: 3280842
Source DB: PubMed Journal: JAMA ISSN: 0098-7484 Impact factor: 56.272